We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
InterMed Discovery Announces Collaboration Agreement with the Lead Discovery Center
News

InterMed Discovery Announces Collaboration Agreement with the Lead Discovery Center

InterMed Discovery Announces Collaboration Agreement with the Lead Discovery Center
News

InterMed Discovery Announces Collaboration Agreement with the Lead Discovery Center

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "InterMed Discovery Announces Collaboration Agreement with the Lead Discovery Center"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

InterMed Discovery (IMD) has announced the start of a screening project for the Lead Discovery Center GmbH (LDC), a Max-Planck-Innovation company.

The LDC was founded in 2008 in close proximity to IMD at the University Campus at Dortmund and forms an essential part of Max-Planck-Innovation's Drug Discovery & Development Center (DDC).

The objective of this collaboration project between IMD and the LDC is to identify naturally derived modulators by screening IMD’s natural product libraries against targets provided by LDC and based on intellectual property previously generated by MPG and the LDC.

IMD will undertake assay establishment, screening, hit identification and hit validation for LDC using its expertise and technology platform with the largest collection of pure natural products (NAT-PURER®) and fractionated extracts (PRE-FRACR®).

“We intend this to be the beginning of a long term relationship with more projects coming in the very near future,” said Bernard Becker, Managing Director of InterMed Discovery. “This is a step forward in our sustainable business growth through integrated research-based value generation validating our strong research capabilities.”

Dr Bert Klebl, Managing Director & CSO added: “The LDC aims to achieve the very highest levels of quality in early drug discovery and this objective is greatly enhanced by the collaboration with InterMed Discovery.”

Advertisement